NO147560B - Analogifremgangsmaate ved fremstilling av terapeutisk aktive indanyl-derivater - Google Patents
Analogifremgangsmaate ved fremstilling av terapeutisk aktive indanyl-derivater Download PDFInfo
- Publication number
- NO147560B NO147560B NO792474A NO792474A NO147560B NO 147560 B NO147560 B NO 147560B NO 792474 A NO792474 A NO 792474A NO 792474 A NO792474 A NO 792474A NO 147560 B NO147560 B NO 147560B
- Authority
- NO
- Norway
- Prior art keywords
- general formula
- indanyl
- nitroindane
- phenoxy
- indane
- Prior art date
Links
- -1 INDANYL Chemical class 0.000 title claims description 23
- 238000000034 method Methods 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 23
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000000676 alkoxyimino group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Chemical group 0.000 claims description 2
- 239000000460 chlorine Chemical group 0.000 claims description 2
- 229910052801 chlorine Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 150000003457 sulfones Chemical class 0.000 claims description 2
- 150000003462 sulfoxides Chemical class 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 150000007857 hydrazones Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003458 sulfonic acid derivatives Chemical class 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- OJNRHKOJADOVAE-UHFFFAOYSA-N 5-bromo-6-nitro-2,3-dihydro-1h-indene Chemical compound C1=C(Br)C([N+](=O)[O-])=CC2=C1CCC2 OJNRHKOJADOVAE-UHFFFAOYSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- 238000009835 boiling Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000001953 recrystallisation Methods 0.000 description 9
- 235000011121 sodium hydroxide Nutrition 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- BVWQEBWCUCGHHZ-UHFFFAOYSA-N n-(1-oxo-6-phenoxy-2,3-dihydroinden-5-yl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=CC=C1 BVWQEBWCUCGHHZ-UHFFFAOYSA-N 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
- PYPIEUKDKXCSSI-UHFFFAOYSA-N 6-phenoxy-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=2CCCC=2C=C1OC1=CC=CC=C1 PYPIEUKDKXCSSI-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 5
- 239000007868 Raney catalyst Substances 0.000 description 4
- 229910000564 Raney nickel Inorganic materials 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 229950005499 carbon tetrachloride Drugs 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 210000000548 hind-foot Anatomy 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- WDYGVVWWRZFQEO-UHFFFAOYSA-N n-(1-oxo-6-phenoxy-2-phenylsulfanyl-2,3-dihydroinden-5-yl)methanesulfonamide Chemical compound O=C1C=2C=C(OC=3C=CC=CC=3)C(NS(=O)(=O)C)=CC=2CC1SC1=CC=CC=C1 WDYGVVWWRZFQEO-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- OQRGTWJAXDMYQY-UHFFFAOYSA-N 5-nitro-6-phenoxy-2,3-dihydro-1h-indene Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1OC1=CC=CC=C1 OQRGTWJAXDMYQY-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- KCPQQVCJZPFLDU-UHFFFAOYSA-N 5-(2-fluorophenoxy)-6-nitro-2,3-dihydro-1h-indene Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1OC1=CC=CC=C1F KCPQQVCJZPFLDU-UHFFFAOYSA-N 0.000 description 2
- YYGNFQHQWUTJNJ-UHFFFAOYSA-N 5-fluoro-6-nitro-2,3-dihydroinden-1-one Chemical compound C1=C(F)C([N+](=O)[O-])=CC2=C1CCC2=O YYGNFQHQWUTJNJ-UHFFFAOYSA-N 0.000 description 2
- ZIVJSZCSWIXYPE-UHFFFAOYSA-N 5-nitro-6-phenylsulfanyl-2,3-dihydro-1h-indene Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1SC1=CC=CC=C1 ZIVJSZCSWIXYPE-UHFFFAOYSA-N 0.000 description 2
- BBXDIZJIVWZLNU-UHFFFAOYSA-N 6-(4-fluorophenoxy)-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=2CCCC=2C=C1OC1=CC=C(F)C=C1 BBXDIZJIVWZLNU-UHFFFAOYSA-N 0.000 description 2
- BDQHCRZTZUVRMT-UHFFFAOYSA-N 6-phenylsulfanyl-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=2CCCC=2C=C1SC1=CC=CC=C1 BDQHCRZTZUVRMT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- GUUVPOWQJOLRAS-UHFFFAOYSA-N Diphenyl disulfide Chemical compound C=1C=CC=CC=1SSC1=CC=CC=C1 GUUVPOWQJOLRAS-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- YADSGOSSYOOKMP-UHFFFAOYSA-N dioxolead Chemical compound O=[Pb]=O YADSGOSSYOOKMP-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- HMCHPJARCSHOPH-UHFFFAOYSA-N n,n-dimethyl-1-(5-nitro-6-phenoxy-2,3-dihydroinden-1-ylidene)methanamine Chemical compound C1=C2C(=CN(C)C)CCC2=CC([N+]([O-])=O)=C1OC1=CC=CC=C1 HMCHPJARCSHOPH-UHFFFAOYSA-N 0.000 description 2
- SEOYFJMPFVYJAQ-UHFFFAOYSA-N n-(3-oxo-6-phenoxy-1,2-dihydroinden-5-yl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2C(=O)CCC=2C=C1OC1=CC=CC=C1 SEOYFJMPFVYJAQ-UHFFFAOYSA-N 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 230000001562 ulcerogenic effect Effects 0.000 description 2
- PWNBOTMWJZFKHV-UHFFFAOYSA-N 1,1,1-trifluoro-n-(6-phenoxy-2,3-dihydro-1h-inden-5-yl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=2CCCC=2C=C1OC1=CC=CC=C1 PWNBOTMWJZFKHV-UHFFFAOYSA-N 0.000 description 1
- FQQLETXDJGPJPY-UHFFFAOYSA-N 1,1,1-trifluoro-n-(6-phenylsulfanyl-2,3-dihydro-1h-inden-5-yl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=2CCCC=2C=C1SC1=CC=CC=C1 FQQLETXDJGPJPY-UHFFFAOYSA-N 0.000 description 1
- QLOKJRIVRGCVIM-UHFFFAOYSA-N 1-[(4-methylsulfanylphenyl)methyl]piperazine Chemical compound C1=CC(SC)=CC=C1CN1CCNCC1 QLOKJRIVRGCVIM-UHFFFAOYSA-N 0.000 description 1
- RGYUHLKLOMGFMI-UHFFFAOYSA-N 1-[6-(2-fluorophenoxy)-5-nitro-2,3-dihydroinden-1-ylidene]-n,n-dimethylmethanamine Chemical compound C1=C2C(=CN(C)C)CCC2=CC([N+]([O-])=O)=C1OC1=CC=CC=C1F RGYUHLKLOMGFMI-UHFFFAOYSA-N 0.000 description 1
- PUTGFEDVECEHKO-UHFFFAOYSA-N 1-[6-(4-fluorophenoxy)-5-nitro-2,3-dihydroinden-1-ylidene]-n,n-dimethylmethanamine Chemical compound C1=C2C(=CN(C)C)CCC2=CC([N+]([O-])=O)=C1OC1=CC=C(F)C=C1 PUTGFEDVECEHKO-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- JYPCAWKGKGAHDQ-UHFFFAOYSA-N 1-chloro-n-(6-phenoxy-2,3-dihydro-1h-inden-5-yl)methanesulfonamide Chemical compound ClCS(=O)(=O)NC1=CC=2CCCC=2C=C1OC1=CC=CC=C1 JYPCAWKGKGAHDQ-UHFFFAOYSA-N 0.000 description 1
- FHTDDANQIMVWKZ-UHFFFAOYSA-N 1h-pyridine-4-thione Chemical compound SC1=CC=NC=C1 FHTDDANQIMVWKZ-UHFFFAOYSA-N 0.000 description 1
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 1
- HFZWRUODUSTPEG-UHFFFAOYSA-N 2,4-dichlorophenol Chemical compound OC1=CC=C(Cl)C=C1Cl HFZWRUODUSTPEG-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- VBKJQYQIMAIQEH-UHFFFAOYSA-N 2-[(6-nitro-2,3-dihydro-1h-inden-5-yl)sulfanyl]pyridine Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1SC1=CC=CC=N1 VBKJQYQIMAIQEH-UHFFFAOYSA-N 0.000 description 1
- IGYXYGDEYHNFFT-UHFFFAOYSA-N 2-chloro-4-fluorophenol Chemical compound OC1=CC=C(F)C=C1Cl IGYXYGDEYHNFFT-UHFFFAOYSA-N 0.000 description 1
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 1
- HFHFGHLXUCOHLN-UHFFFAOYSA-N 2-fluorophenol Chemical compound OC1=CC=CC=C1F HFHFGHLXUCOHLN-UHFFFAOYSA-N 0.000 description 1
- WDNBURPWRNALGP-UHFFFAOYSA-N 3,4-Dichlorophenol Chemical compound OC1=CC=C(Cl)C(Cl)=C1 WDNBURPWRNALGP-UHFFFAOYSA-N 0.000 description 1
- JVLFMTZUPSBCNJ-UHFFFAOYSA-N 3,5-difluoropyridin-2-amine Chemical compound NC1=NC=C(F)C=C1F JVLFMTZUPSBCNJ-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- UGEJOEBBMPOJMT-UHFFFAOYSA-N 3-(trifluoromethyl)phenol Chemical compound OC1=CC=CC(C(F)(F)F)=C1 UGEJOEBBMPOJMT-UHFFFAOYSA-N 0.000 description 1
- AIEAPUYXEQNISH-UHFFFAOYSA-N 3-[(6-nitro-2,3-dihydro-1h-inden-5-yl)oxy]pyridine Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1OC1=CC=CN=C1 AIEAPUYXEQNISH-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- HORNXRXVQWOLPJ-UHFFFAOYSA-N 3-chlorophenol Chemical compound OC1=CC=CC(Cl)=C1 HORNXRXVQWOLPJ-UHFFFAOYSA-N 0.000 description 1
- PWRBCZZQRRPXAB-UHFFFAOYSA-N 3-chloropyridine Chemical compound ClC1=CC=CN=C1 PWRBCZZQRRPXAB-UHFFFAOYSA-N 0.000 description 1
- SJTBRFHBXDZMPS-UHFFFAOYSA-N 3-fluorophenol Chemical compound OC1=CC=CC(F)=C1 SJTBRFHBXDZMPS-UHFFFAOYSA-N 0.000 description 1
- OKIHXNKYYGUVTE-UHFFFAOYSA-N 4-Fluorothiophenol Chemical compound FC1=CC=C(S)C=C1 OKIHXNKYYGUVTE-UHFFFAOYSA-N 0.000 description 1
- AXASPCIBDBIQAT-UHFFFAOYSA-N 4-[(6-nitro-2,3-dihydro-1h-inden-5-yl)sulfanyl]pyridine Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1SC1=CC=NC=C1 AXASPCIBDBIQAT-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- RHPUJHQBPORFGV-UHFFFAOYSA-N 4-chloro-2-methylphenol Chemical compound CC1=CC(Cl)=CC=C1O RHPUJHQBPORFGV-UHFFFAOYSA-N 0.000 description 1
- VZXOZSQDJJNBRC-UHFFFAOYSA-N 4-chlorobenzenethiol Chemical compound SC1=CC=C(Cl)C=C1 VZXOZSQDJJNBRC-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
- MBIAXYRGQVGWAD-UHFFFAOYSA-N 5-(2,4-dichlorophenoxy)-6-nitro-2,3-dihydro-1h-indene Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1OC1=CC=C(Cl)C=C1Cl MBIAXYRGQVGWAD-UHFFFAOYSA-N 0.000 description 1
- YJWHXXHNSWWBQZ-UHFFFAOYSA-N 5-(2-chloro-4-fluorophenoxy)-6-nitro-2,3-dihydro-1h-indene Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1OC1=CC=C(F)C=C1Cl YJWHXXHNSWWBQZ-UHFFFAOYSA-N 0.000 description 1
- YTPGTTFQYDIXQF-UHFFFAOYSA-N 5-(2-chlorophenoxy)-6-nitro-2,3-dihydro-1h-indene Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1OC1=CC=CC=C1Cl YTPGTTFQYDIXQF-UHFFFAOYSA-N 0.000 description 1
- FFJQLJLMERMQCX-UHFFFAOYSA-N 5-(2-methylphenoxy)-6-nitro-2,3-dihydro-1h-indene Chemical compound CC1=CC=CC=C1OC(C(=C1)[N+]([O-])=O)=CC2=C1CCC2 FFJQLJLMERMQCX-UHFFFAOYSA-N 0.000 description 1
- RYUOQJUBCVVIAC-UHFFFAOYSA-N 5-(3,4-dichlorophenoxy)-6-nitro-2,3-dihydro-1h-indene Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1OC1=CC=C(Cl)C(Cl)=C1 RYUOQJUBCVVIAC-UHFFFAOYSA-N 0.000 description 1
- BABAIYSGPOLZGG-UHFFFAOYSA-N 5-(3-fluorophenoxy)-6-nitro-2,3-dihydro-1h-indene Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1OC1=CC=CC(F)=C1 BABAIYSGPOLZGG-UHFFFAOYSA-N 0.000 description 1
- REBMGSHQLQBKCC-UHFFFAOYSA-N 5-(4-bromophenoxy)-6-nitro-2,3-dihydro-1h-indene Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1OC1=CC=C(Br)C=C1 REBMGSHQLQBKCC-UHFFFAOYSA-N 0.000 description 1
- GOYSYSPDXHHGKV-UHFFFAOYSA-N 5-(4-chlorophenoxy)-6-nitro-2,3-dihydro-1h-indene Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1OC1=CC=C(Cl)C=C1 GOYSYSPDXHHGKV-UHFFFAOYSA-N 0.000 description 1
- MFZWZRALRGKNGK-UHFFFAOYSA-N 5-(4-chlorophenyl)sulfanyl-6-nitro-2,3-dihydro-1h-indene Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1SC1=CC=C(Cl)C=C1 MFZWZRALRGKNGK-UHFFFAOYSA-N 0.000 description 1
- BKDBQNGKAXPOQZ-UHFFFAOYSA-N 5-(4-fluorophenoxy)-6-nitro-2,3-dihydro-1h-indene Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1OC1=CC=C(F)C=C1 BKDBQNGKAXPOQZ-UHFFFAOYSA-N 0.000 description 1
- BSYFIHCQPWHNJQ-UHFFFAOYSA-N 5-(4-fluorophenyl)sulfanyl-6-nitro-2,3-dihydro-1h-indene Chemical compound [O-][N+](=O)C1=CC=2CCCC=2C=C1SC1=CC=C(F)C=C1 BSYFIHCQPWHNJQ-UHFFFAOYSA-N 0.000 description 1
- BFTROKIGVIXAKD-UHFFFAOYSA-N 5-(4-methylphenoxy)-6-nitro-2,3-dihydro-1h-indene Chemical compound C1=CC(C)=CC=C1OC(C(=C1)[N+]([O-])=O)=CC2=C1CCC2 BFTROKIGVIXAKD-UHFFFAOYSA-N 0.000 description 1
- VXPUTENETGMKKM-UHFFFAOYSA-N 5-(4-tert-butylphenyl)sulfanyl-6-nitro-2,3-dihydro-1h-indene Chemical compound C1=CC(C(C)(C)C)=CC=C1SC(C(=C1)[N+]([O-])=O)=CC2=C1CCC2 VXPUTENETGMKKM-UHFFFAOYSA-N 0.000 description 1
- RKXYIUBGXCPBFS-UHFFFAOYSA-N 5-amino-6-(2-fluorophenoxy)-2,3-dihydroinden-1-one Chemical compound NC1=CC=2CCC(=O)C=2C=C1OC1=CC=CC=C1F RKXYIUBGXCPBFS-UHFFFAOYSA-N 0.000 description 1
- MDINQKAHZLWFQQ-UHFFFAOYSA-N 5-amino-6-(3-chlorophenoxy)-2,3-dihydroinden-1-one Chemical compound NC1=CC=2CCC(=O)C=2C=C1OC1=CC=CC(Cl)=C1 MDINQKAHZLWFQQ-UHFFFAOYSA-N 0.000 description 1
- RLSPDSVLSNTWIR-UHFFFAOYSA-N 5-amino-6-(4-chlorophenoxy)-2,3-dihydroinden-1-one Chemical compound NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(Cl)C=C1 RLSPDSVLSNTWIR-UHFFFAOYSA-N 0.000 description 1
- UPYPTDDLVMLJSH-UHFFFAOYSA-N 5-amino-6-(4-fluorophenoxy)-2,3-dihydroinden-1-one Chemical compound NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(F)C=C1 UPYPTDDLVMLJSH-UHFFFAOYSA-N 0.000 description 1
- VJDKXBSDZLSGIW-UHFFFAOYSA-N 5-amino-6-phenoxy-2,3-dihydroinden-1-one Chemical compound NC1=CC=2CCC(=O)C=2C=C1OC1=CC=CC=C1 VJDKXBSDZLSGIW-UHFFFAOYSA-N 0.000 description 1
- WVPPBVAMKNQXJA-UHFFFAOYSA-N 5-fluoro-2,3-dihydroinden-1-one Chemical compound FC1=CC=C2C(=O)CCC2=C1 WVPPBVAMKNQXJA-UHFFFAOYSA-N 0.000 description 1
- ZGUMTMQVISBZLJ-UHFFFAOYSA-N 5-nitro-6-phenoxy-2,3-dihydro-1h-indene-1-carbonitrile Chemical compound [O-][N+](=O)C1=CC=2CCC(C#N)C=2C=C1OC1=CC=CC=C1 ZGUMTMQVISBZLJ-UHFFFAOYSA-N 0.000 description 1
- VUKVRULQEFBCAS-UHFFFAOYSA-N 5-nitro-6-phenoxy-2,3-dihydroinden-1-one Chemical compound [O-][N+](=O)C1=CC=2CCC(=O)C=2C=C1OC1=CC=CC=C1 VUKVRULQEFBCAS-UHFFFAOYSA-N 0.000 description 1
- FPRHZTXVICZAOZ-UHFFFAOYSA-N 6-(2,4-dichlorophenoxy)-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=2CCCC=2C=C1OC1=CC=C(Cl)C=C1Cl FPRHZTXVICZAOZ-UHFFFAOYSA-N 0.000 description 1
- MDRFPJNYTOPMII-UHFFFAOYSA-N 6-(2-chlorophenoxy)-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=2CCCC=2C=C1OC1=CC=CC=C1Cl MDRFPJNYTOPMII-UHFFFAOYSA-N 0.000 description 1
- YTMYLEMCMZYEFY-UHFFFAOYSA-N 6-(2-methylphenoxy)-2,3-dihydro-1h-inden-5-amine Chemical compound CC1=CC=CC=C1OC(C(=C1)N)=CC2=C1CCC2 YTMYLEMCMZYEFY-UHFFFAOYSA-N 0.000 description 1
- FVJXSRUKLSPIJY-UHFFFAOYSA-N 6-(3,4-dichlorophenoxy)-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=2CCCC=2C=C1OC1=CC=C(Cl)C(Cl)=C1 FVJXSRUKLSPIJY-UHFFFAOYSA-N 0.000 description 1
- NZCAZIPNYGLFKE-UHFFFAOYSA-N 6-(3-chlorophenoxy)-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=2CCCC=2C=C1OC1=CC=CC(Cl)=C1 NZCAZIPNYGLFKE-UHFFFAOYSA-N 0.000 description 1
- DFOAANPPMMDVJG-UHFFFAOYSA-N 6-(3-chlorophenoxy)-5-nitro-2,3-dihydroinden-1-one Chemical compound [O-][N+](=O)C1=CC=2CCC(=O)C=2C=C1OC1=CC=CC(Cl)=C1 DFOAANPPMMDVJG-UHFFFAOYSA-N 0.000 description 1
- MDKJCGGIDIBDDM-UHFFFAOYSA-N 6-(3-fluorophenoxy)-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=2CCCC=2C=C1OC1=CC=CC(F)=C1 MDKJCGGIDIBDDM-UHFFFAOYSA-N 0.000 description 1
- AHYIKQOYHORPFI-UHFFFAOYSA-N 6-(4-bromophenoxy)-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=2CCCC=2C=C1OC1=CC=C(Br)C=C1 AHYIKQOYHORPFI-UHFFFAOYSA-N 0.000 description 1
- KHTMVGSUIYYFFL-UHFFFAOYSA-N 6-(4-chlorophenoxy)-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=2CCCC=2C=C1OC1=CC=C(Cl)C=C1 KHTMVGSUIYYFFL-UHFFFAOYSA-N 0.000 description 1
- RWTWOIULHCTKIL-UHFFFAOYSA-N 6-(4-chlorophenoxy)-5-nitro-2,3-dihydroinden-1-one Chemical compound [O-][N+](=O)C1=CC=2CCC(=O)C=2C=C1OC1=CC=C(Cl)C=C1 RWTWOIULHCTKIL-UHFFFAOYSA-N 0.000 description 1
- UFQORERRCPFPEW-UHFFFAOYSA-N 6-(4-chlorophenyl)sulfanyl-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=2CCCC=2C=C1SC1=CC=C(Cl)C=C1 UFQORERRCPFPEW-UHFFFAOYSA-N 0.000 description 1
- NVEYSVMRFJENIZ-UHFFFAOYSA-N 6-(4-fluorophenoxy)-5-nitro-2,3-dihydroinden-1-one Chemical compound [O-][N+](=O)C1=CC=2CCC(=O)C=2C=C1OC1=CC=C(F)C=C1 NVEYSVMRFJENIZ-UHFFFAOYSA-N 0.000 description 1
- MPWAPKWLJHXGCV-UHFFFAOYSA-N 6-(4-methylphenoxy)-2,3-dihydro-1h-inden-5-amine Chemical compound C1=CC(C)=CC=C1OC(C(=C1)N)=CC2=C1CCC2 MPWAPKWLJHXGCV-UHFFFAOYSA-N 0.000 description 1
- YHHJFNOWTYCPOD-UHFFFAOYSA-N 6-(4-tert-butylphenyl)sulfanyl-2,3-dihydro-1h-inden-5-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1SC(C(=C1)N)=CC2=C1CCC2 YHHJFNOWTYCPOD-UHFFFAOYSA-N 0.000 description 1
- LJMHNYHKDQZZQA-UHFFFAOYSA-N 6-[3-(trifluoromethyl)phenoxy]-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=2CCCC=2C=C1OC1=CC=CC(C(F)(F)F)=C1 LJMHNYHKDQZZQA-UHFFFAOYSA-N 0.000 description 1
- WKGWQQHJJODARU-UHFFFAOYSA-N 6-amino-5-phenoxy-2,3-dihydroinden-1-one Chemical compound NC1=CC=2C(=O)CCC=2C=C1OC1=CC=CC=C1 WKGWQQHJJODARU-UHFFFAOYSA-N 0.000 description 1
- WTPWZZFPDWSMCS-UHFFFAOYSA-N 6-amino-5-phenylsulfanyl-2,3-dihydroinden-1-one Chemical compound NC1=CC=2C(=O)CCC=2C=C1SC1=CC=CC=C1 WTPWZZFPDWSMCS-UHFFFAOYSA-N 0.000 description 1
- AZAWEMHHJLYLBA-UHFFFAOYSA-N 6-nitro-5-phenoxy-2,3-dihydroinden-1-one Chemical compound [O-][N+](=O)C1=CC=2C(=O)CCC=2C=C1OC1=CC=CC=C1 AZAWEMHHJLYLBA-UHFFFAOYSA-N 0.000 description 1
- MAHJPOIMKGNNGM-UHFFFAOYSA-N 6-nitro-5-phenylsulfanyl-2,3-dihydroinden-1-one Chemical compound [O-][N+](=O)C1=CC=2C(=O)CCC=2C=C1SC1=CC=CC=C1 MAHJPOIMKGNNGM-UHFFFAOYSA-N 0.000 description 1
- CCJVWJUKHZWNPI-UHFFFAOYSA-N 6-pyridin-2-ylsulfanyl-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=2CCCC=2C=C1SC1=CC=CC=N1 CCJVWJUKHZWNPI-UHFFFAOYSA-N 0.000 description 1
- RCIAMVMHIIUDRU-UHFFFAOYSA-N 6-pyridin-4-ylsulfanyl-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=2CCCC=2C=C1SC1=CC=NC=C1 RCIAMVMHIIUDRU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001181114 Neta Species 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- YBVPWLHQQWQJAR-UHFFFAOYSA-N [Cl+].[Cu+] Chemical compound [Cl+].[Cu+] YBVPWLHQQWQJAR-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical compound NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- VZDYWEUILIUIDF-UHFFFAOYSA-J cerium(4+);disulfate Chemical compound [Ce+4].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O VZDYWEUILIUIDF-UHFFFAOYSA-J 0.000 description 1
- 229910000355 cerium(IV) sulfate Inorganic materials 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- AJYXQZZAMKCOJH-UHFFFAOYSA-N chloromethylsulfonyl chloromethanesulfonate Chemical compound ClCS(=O)(=O)OS(=O)(=O)CCl AJYXQZZAMKCOJH-UHFFFAOYSA-N 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- QDYBCIWLGJMJGO-UHFFFAOYSA-N dinitromethanone Chemical class [O-][N+](=O)C(=O)[N+]([O-])=O QDYBCIWLGJMJGO-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000009841 epithelial lesion Effects 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- CCJXQRNXZKSOGJ-UHFFFAOYSA-N ethylsulfonyl ethanesulfonate Chemical compound CCS(=O)(=O)OS(=O)(=O)CC CCJXQRNXZKSOGJ-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- HXRAMSFGUAOAJR-UHFFFAOYSA-N n,n,n',n'-tetramethyl-1-[(2-methylpropan-2-yl)oxy]methanediamine Chemical compound CN(C)C(N(C)C)OC(C)(C)C HXRAMSFGUAOAJR-UHFFFAOYSA-N 0.000 description 1
- GNCBXNYKGZPFRO-UHFFFAOYSA-N n-(1-amino-6-phenoxy-2,3-dihydro-1h-inden-5-yl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(N)C=2C=C1OC1=CC=CC=C1 GNCBXNYKGZPFRO-UHFFFAOYSA-N 0.000 description 1
- SPCGQUURUHFFMB-UHFFFAOYSA-N n-(1-cyano-6-phenoxy-2,3-dihydro-1h-inden-5-yl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(C#N)C=2C=C1OC1=CC=CC=C1 SPCGQUURUHFFMB-UHFFFAOYSA-N 0.000 description 1
- DEWAJYXNNWCWJP-UHFFFAOYSA-N n-(1-hydroxyimino-6-phenoxy-2,3-dihydroinden-5-yl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=NO)C=2C=C1OC1=CC=CC=C1 DEWAJYXNNWCWJP-UHFFFAOYSA-N 0.000 description 1
- FWXNSWGAMFXSPN-UHFFFAOYSA-N n-(1-methoxyimino-6-phenoxy-2,3-dihydroinden-5-yl)methanesulfonamide Chemical compound C1=C2C(=NOC)CCC2=CC(NS(C)(=O)=O)=C1OC1=CC=CC=C1 FWXNSWGAMFXSPN-UHFFFAOYSA-N 0.000 description 1
- ZPTHYFLPJBOJCH-UHFFFAOYSA-N n-(3-oxo-6-phenylsulfanyl-1,2-dihydroinden-5-yl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2C(=O)CCC=2C=C1SC1=CC=CC=C1 ZPTHYFLPJBOJCH-UHFFFAOYSA-N 0.000 description 1
- YTNLNHLOXYAXOG-UHFFFAOYSA-N n-(4-chlorophenoxy)-2,3-dihydro-1h-inden-5-amine Chemical compound C1=CC(Cl)=CC=C1ONC1=CC=C(CCC2)C2=C1 YTNLNHLOXYAXOG-UHFFFAOYSA-N 0.000 description 1
- AVEVSZXVFYABDM-UHFFFAOYSA-N n-(6-phenoxy-2,3-dihydro-1h-inden-5-yl)ethanesulfonamide Chemical compound CCS(=O)(=O)NC1=CC=2CCCC=2C=C1OC1=CC=CC=C1 AVEVSZXVFYABDM-UHFFFAOYSA-N 0.000 description 1
- HCBMEMPZHUPGHY-UHFFFAOYSA-N n-(6-phenoxy-2,3-dihydro-1h-inden-5-yl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCCC=2C=C1OC1=CC=CC=C1 HCBMEMPZHUPGHY-UHFFFAOYSA-N 0.000 description 1
- LMQOHUWEDJFZLA-UHFFFAOYSA-N n-(6-phenylsulfanyl-2,3-dihydro-1h-inden-5-yl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCCC=2C=C1SC1=CC=CC=C1 LMQOHUWEDJFZLA-UHFFFAOYSA-N 0.000 description 1
- RPFRQDPIUQYOLY-UHFFFAOYSA-N n-(6-pyridin-4-ylsulfanyl-2,3-dihydro-1h-inden-5-yl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCCC=2C=C1SC1=CC=NC=C1 RPFRQDPIUQYOLY-UHFFFAOYSA-N 0.000 description 1
- RXJFAMXYFXHQFG-UHFFFAOYSA-N n-[1-oxo-6-phenoxy-2,2-bis(phenylsulfanyl)-3h-inden-5-yl]methanesulfonamide Chemical compound O=C1C=2C=C(OC=3C=CC=CC=3)C(NS(=O)(=O)C)=CC=2CC1(SC=1C=CC=CC=1)SC1=CC=CC=C1 RXJFAMXYFXHQFG-UHFFFAOYSA-N 0.000 description 1
- GCQBPXGXNPMPNK-UHFFFAOYSA-N n-[2-(benzenesulfinyl)-1-oxo-6-phenoxy-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CC(S(=O)C=3C=CC=CC=3)C(=O)C=2C=C1OC1=CC=CC=C1 GCQBPXGXNPMPNK-UHFFFAOYSA-N 0.000 description 1
- DQIZANOEMRQGLW-UHFFFAOYSA-N n-[6-(2-fluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=CC=C1F DQIZANOEMRQGLW-UHFFFAOYSA-N 0.000 description 1
- DZGRQGKYBYNIOQ-UHFFFAOYSA-N n-[6-(2-methylphenoxy)-2,3-dihydro-1h-inden-5-yl]methanesulfonamide Chemical compound CC1=CC=CC=C1OC(C(=C1)NS(C)(=O)=O)=CC2=C1CCC2 DZGRQGKYBYNIOQ-UHFFFAOYSA-N 0.000 description 1
- YSGKHKGURPPFLM-UHFFFAOYSA-N n-[6-(3,4-dichlorophenoxy)-2,3-dihydro-1h-inden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCCC=2C=C1OC1=CC=C(Cl)C(Cl)=C1 YSGKHKGURPPFLM-UHFFFAOYSA-N 0.000 description 1
- PWLYYCXYMUAPOV-UHFFFAOYSA-N n-[6-(3-chlorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=CC(Cl)=C1 PWLYYCXYMUAPOV-UHFFFAOYSA-N 0.000 description 1
- PHPFQTCEMXGZFJ-UHFFFAOYSA-N n-[6-(3-fluorophenoxy)-2,3-dihydro-1h-inden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCCC=2C=C1OC1=CC=CC(F)=C1 PHPFQTCEMXGZFJ-UHFFFAOYSA-N 0.000 description 1
- DVBLVNUQAFGMNI-UHFFFAOYSA-N n-[6-(4-bromophenoxy)-2,3-dihydro-1h-inden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCCC=2C=C1OC1=CC=C(Br)C=C1 DVBLVNUQAFGMNI-UHFFFAOYSA-N 0.000 description 1
- LIOFQCWKFQYUNI-UHFFFAOYSA-N n-[6-(4-chlorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(Cl)C=C1 LIOFQCWKFQYUNI-UHFFFAOYSA-N 0.000 description 1
- XTDBSSICEFGNDC-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(F)C=C1 XTDBSSICEFGNDC-UHFFFAOYSA-N 0.000 description 1
- HQMBTOUXOYNNGD-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)-2,3-dihydro-1h-inden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCCC=2C=C1OC1=CC=C(F)C=C1 HQMBTOUXOYNNGD-UHFFFAOYSA-N 0.000 description 1
- PCUOXCKGUNVECA-UHFFFAOYSA-N n-[6-(4-fluorophenyl)sulfanyl-2,3-dihydro-1h-inden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCCC=2C=C1SC1=CC=C(F)C=C1 PCUOXCKGUNVECA-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C205/38—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. nitrodiphenyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Description
Foreliggende oppfinnelse angår analogifremgangsmåte ved fremstilling av nye, terapeutisk aktive indanylderivater,
som angitt i kravet.
Ifølge oppfinnelsen kan gruppen
eller
indanyl- *
derivatet med formel I stå i neta- eller para-stilling til sub-
stituenten Ar-X på fenylringen.
Indanylderivatene med den generelle formel I er
farmakologisk virksommme forbindelser, som eksempelvis utmerker seg ved en analgetisk, antipyretisk, trombocytaggregasjonshemmende, diuretisk og særlig ved en antiflog istisk virksomhet. En særlig fordel ved disse forbindelser ligger i at de utmerker seg ved en stor avstand mellom terapeutisk virksomhet og uønsket bivirkning (særlig ulcerogen virksomhet). Dessuten er det bemerkelsesverdig at disse forbindelser neppe hemmer prostaglandinsyntesen.
Den antiflog istiske virksomhet av fremgangsmåteforbindelsene
kan bestemmes ved hjelp av den såkalte adjuvans-arthrit is-prøve,
som utføres som følger:
Der anvendes hun- og hanrotter av stammen Lewis (LEW) i
vektområdet mellom HO og 190 g. Dyrene får drikkevann og altromin-pressfor ad libitum.
For hver dosegruppe anvendes 10 rotter.
Mycobacter ium butyrLcum fra firmaet Dif co, Detroit anvendes
som irritasjonsmiddel. En suspensjon av 0,5 mg Mycobacterium butyricuin i 0,1 ml tyntflytende paraffin (DAB 7) injiseres sub-
plantart i den høyre bakpote.
Forsøksforbindelsen gies daglig oralt i 4 dager fra den
11. forseJksriag. Forbindelsene administreres som klar, vandig oppløsning eller som krystallsuspensjon under tilsetning av "Myri 53" (85 rag %) i isotonisk nat riumkloridoppløsning.
Forsøksmetode:
Rottene inndeles mest mulig jevnt med hensyn til kroppsvekt i forskjellige grupper» Efter pletysmografisk voluunåling av den høyre bakpote injiseres 0,1 ml adjuvans subplantart i disse. Den høyre bakpote måles fra den 14• forsøksdag inntil slutten av for-søket o Forsøksvarigheten utgjør 3 uker.
Den legning av bakpoten som oppnåes ved den gitte dose, bestemmes. En hyppig komplikasjon ved terapien med ikke-steroide inf lammasjonshemmere er opptreden av mavesår. Denne bivirkning kan påvises i dyreforsøk idet ved forutgitt dose antallet av iakt-tatte lesjoner og deres totalflate bestemmes. Mavesårprøven ut-føres som følger.
Der anvendes Wistar-hanrotter (SPF). Dyrene ligger i et vektområde på 130 t IO g. 16 timer før begynnelsen av forsøket taes dyrene fra foret, men de får vann ad libitum.
Der anvendes 5 dyr pr. dose. Forbindelsene administreres en gang oralt, oppløst i nat riumklorid eller som krystallsuspensjon under tilsetning av 85 mg % "Myri 53" <> 3 timer efter administrasjon av forbindelsen injiseres 1 ml av en 3%-ig oppløsning av farvestoffet "Diphenylreinblau" intra-venøst , og dyrene avlives. Maven skjæres ut og undersøkes mikro-skopisk på antall og tota Istørrelse av epit el lesjoner og ulcera som trer frem ved farvestoffanrikninger.
Den efterfølgende tabell viser de i disse forsøk erholdte resultater med fremgangsmåte.forbindelser sammenlignet med det tid-ligere kjente Indomethacin (forbindelse 1). Av disse resultater fremgår fremgangsmåtenes overlegenhet, særlig med hensyn til deres overlegne skille mellom ant i inflammatorisk og ulcerogen virksomhet.
De nye fremgangsraåteforbindelser egner seg i kombinasjon med de i den galeniske farmasi vanlige bæremidler til behandling f.eks., av akutt og kronisk polyarthritis, neurodermitis, asthma bron-chiale, høyfeber o.a.
Fremstillingen av legemiddelspesialitetere skjer på vanlig vis idet virkestoffet opparbeides med egnede tilsetninger, bærere og smakskorrigenser til de ønskede administrasjonsformer som tabletter, dragéer, kapsler, oppløsninger, inhaleringsmidler etc.
For oral anvendelse er særlig egnet tabletter, dragéer og kapsler, som eksempelvis inneholder 1 til 250 mg virkestoff og 50 mg til 2 g farmakologisk uvirksom bærer, som f.eks. lactose, amylose, talkum, gelatin, magnesiumstearat og lignende, såvel som de vanlige tilsetninger.
De nye indanylderivater med den generelle formel I fremstilles ved i og for seg kjente fremgangsmåter. En egnet frem-stillingsmåte er f.eks. de i hovedkravet angitte synteser.
Kondensasjonen av forbindelsene med den generelle formel II med sulfonsyreklorider eller anhydrider med den generelle formel III ved fremgangsmåten skjer under kjente beting-elser, eksempelvis idet man omsetter sulfonsyrekloridet i nærvær av basiske katalysatorer som natriumcarbonat, natriumhydroxyd, kaliumbicarbonat, kaliumcarbonat, pyridin, lutidin eller collidin, med forbindelsene med den generelle formel II.
Oxydasjonen av methylengruppen til den tilsvarende carbonyl-gruppe ifølge fremgangsmåtevariant a kan eksempelvis utføres med kaliumpermanganat i alkalisk, nøytral eller svakt sur vandig oppløsning eller ved hjelp av en oppløsning av krom(VI)-oxyd i iseddik ved en temperatur fra -10°C til 110°C.
Fremgangsmåtevariant ^ kan eksempelvis utføres på den måte
at utgangsforbindelsene omsettes i et aprotisk oppløsningsmiddel (pyridin, dimethylformamid, hexamethylfosforsyretriamid, dioxan, tetrahydrofuran, etc.) med et alkalimetallhydrid eller alkali-metallamid (som f.eks. natriumhydrid eller lithiumdiisopropylamid), og at man lar det ønskede disulfid' innvirke på den erholdte reak-sjonsblanding. Reaksjonen utføres fortrinnsvis ved en reaksjons-temperatur fra -6o°C til +20°C.
Den eventuelt påfølgende oxydasjon av thioforbindelsene med
sulfoxydene eller sulfonene med den generelle formel 1 skjer på
i og for seg kjent vis.
Ved denne reaksjon kan man som oxydasjonsmiddel eksempelvis anvende persyrer, som pereddiksyre, perbenzoesyre eller m-klor-perbenzoesyre, hydrogenperoxyd, kinoner, som 2,3-diklor-5,6-dicyanobenzokinon, IV- til VII-verdige metalloxyder eller -salter, som bly(IV)-oxyd, mangan(IV)-oxyd, krom(VI)-oxyd, cerium(IV)-sulfat, kaliumkromat, kaliumdikromat, kaliumpermanganat eller oxyderende halogenforbindelser, som jod, nat riumperjodat, N-brom-succinimid, N-klorsuccinimid eller nat riumklorLd.
Hvis man til denne oxydasjon anvender hydrogenperoxyd eller metalloxyder eller -salter, er det hensiktsmessig å utføre oxydasjonen i nærvær av syrer. Egnede syrer er mineralsyrer, som saltsyre eller svovelsyre eller lavere carboxylsyrer, som eddiksyre eller propionsyre.
Som oppløsningsmiddel kan man ved denne reaksjon anvende såvel protiske som aprotiske inerte oppløsningsmidler. Egnede oppløsningsmidler er f.eks. lavere carboxylsyrer, som eddiksyre eller propionsyre, t-alkoholer, som t-butanol, ketoner som aceton, methylethylketon eller cyclohexanon, ethere som diethyl-ether, diisopropylether, tetrahydrofuran, dioxan eller glycol-dimethylether, hydrocarboner, som benzen eller toluen eller klorerte hydrocarboner , som methylenklorid, kloroform, carbontetraklorid, tetraklorethan eller klorbenzen. Ved fremstilling av sulfoner med den generelle formel I anvendes fortrinnsvis eddiksyre som oppløs-ningsmiddel. Fremstillingen av sulfoxydene skjer fortrinnsvis i aceton som oppiøsningsmiddel.
Fremgangsmåt evariant c utføres fortrinnsvis i et polart opp]osningsmiddel (eksempelvis en lavere alkohol, som methanol, ethanol eller isopropanol eller en lavere carboxylsyre som eddiksyre) ved en reaks jonst empe r a t ur fra -10° til HO°C.
Fremgangsmåt evariant d kan utføres på den måte at man reduserer utgangsforbindeisene med komplekse metallhydrider, som f.eks. natriumborhydrid (i en lavere alkohol, som methanol.
ethanol eller isopropanol som oppløsning-middel) eventuelt under tilsetning av bort rifluorid eller trifluoreddiksyre, eller lithiumaluminiumhydrid (i en polar ether som tetrahydrofuran eller dioxan som oppløsningsmiddel).
På den annen side kan imidlertid denne variant også utføres ved at utgangsforbindelsen hydreres i nærvær av hydreringskata-lysatorer (Raney-nikkel, platinaoxyd, palladium-dyrekull, etc.) med hydrogen ved 1 - 150 atm trykk„
Utgangsforbindelsene for foreliggende fremgangsmåte ifølge hovedkravet er kjente og kan fremstilles på kjent vis.
Således kan f.eks. forbindelsene med den generelle formel II fremstilles ved kondensasjon av forbindelser med den generelle formel VI med forbindelsene med den generelle formel V og på-følgende reduksjon av de erholdte nitroforbindelser med den generelle formel VII.
hvor Ar er en fenyt eller pyridyl-gruppe som eventuelt er substituert med halogen., alkyl méd 1 - 4 carbonatomer, eller trifluormethyl, x er oxycen eller svovel,
hvor Y er oxo, hydroxyimino, alkoxyimino med
1-4 carbonatomer, fenylhydrazono eller p-toluensulfonylhydrazono.
Z er hydroxy, amino eller cyano, W er klor, brom eller
jod, og n er 0, 1 eller 2.
Betingelsene under hvilke disse utgangsforbindelser kan fremstilles syntetisk, er beskrevet i de efterfølgende eksempler ved utvalgte representanter. De etterfølgende eksempler tjener til å belyse foreliggende fremgangsmåte.
Eksempel 1
a) 12,1 g 5-brom-6-n.itroindan, 0,75 g kobber (I)-klorid , 17>39 kaliumcarbonat og 18,4 g fenol kokes i 3 timer i absolutt pyridin
under tilbakeløp.. Reaksjons bl and ingen inndampes i vakuum, residuet tilsettes kloroform og suges av fra uoppløselig materiale. Morluten utrystes tre ganger med 1 n natronlut og 1 n saltsyre og inndampes i vakuum. Efter destillasjon i vakuum får man 11,5 g 5-nitro-6-fenoxyindan med kokepunkt Kp^ l63-l65°C.
o 0,Oi
punkt: 41 C (hexan).
b) En oppløsning av 17»7 g 5-nitro-6-fenoxyindan i 500 ml methanol hydrogeneres i nærvær av 15 g Raney-nikkel i 4 timer
ved 70°C. Katalysatoren frafiltre res, der inndampes i vakuum og omkrystalliseres fra vandig ethanol. Man får 12,9 g 6-fenoxy-5-indanylamin med smp. 62°c.
c) En oppløsning av 7,8 g 6~fenoxy-5-indany1 am in i 50 ml absolutt pyridin tildryppes ved 0°C 4 ml methansulfonklorid i
lopet av IO minutter. Der omrøres i 3 timer ved 0°C og l6 timer ved værel set ernpe rat u r og inndampes i vakuum. Residuet taes opp i kloroform, utrystes tre ganger med 1 n saltsyre og inndampes i vakuum. Derpå orakryst a 11 iseres residuet fra vandig ethanol, og man får 9,5 g >' - ( 6 -f enoxy - 5 - i ndany 1 ) -mer hans ul f onam id med smp. 130°C.
Eksempel 2
Analogt med eksempel 1 fåes ved å gå ut fra 5-b.rom-6-nit ro - indan og 4-klorfenol:
a) 5-(4-klorfenovy)-6-nitroindan med kokepunkt KpQ ^
l65-l68°C og med smp. 67°C (hexan),
b) 6-(4-klorfenoxy)-5-indanylamin med kokepunkt 66°C,
c) N6-(4-klorfenoxy)-5-indanyl]-methansulfonamid med smp. 57°C,
Eksempel 3
Analogt med eksempel 1 fåes ved å gå ut fra 5-brom-6-nitroindan og p-cresol:
a) 5-nitro-6-(4-tolyloxy)-indan med kokepunkt Kp _
-i o u>uo
168-173 C og smp. 58 C (hexan),
b) 6-(4-tolyloxy)-5-indanylamin som olje,
c) N-j 6-(4-tolyloxy)-5-indanyl]-methansulfonamid med kokepunkt 139°C.
Eksempel 4
Analogt med eksempel 1 fåes ved å gå ut fra 5-brom-6-nitroindan og 4-fluorfenol: a) 5-(4~f luorf enoxy) -6-nit roindan med kokepunkt KpQ °<9> me(3 smp. 63°C (hexan),
b) 6-(4-fiuorfenoxy)-5-indanylamin med smp. 72°C,
c) N-j6-(4-fluorfenoxy)-5-indanyl]-methansulfonamid med
smp. 100°C.
Eksempel 5
Analogt med eksempel 1 fåes ved å gå ut fra 5-brom-6-nitroindan og 3-trifluormethylfenol: a) 5-nitro-5-(3-trLfluormethylfenoxy)-indan med kokepunkt Kp0,03 L55-l63°C og med smp. 69°c (hexan),
b) 6-(3-trifluormethylfenoxy)-5-indanylamin som olje,
c) N-: 6-(3-t rifluormethylfenoxy)-5-indanyl]-methansulfonam id
med smp. 8-'-°C.
E kserapel 6
Analogt med eksempel 1 får man ved å gå ut fra 5-t>rom-6-nitroindan og 4-klor-2-methylfenol:
a) 5-(4-klor-2-mexhylfenoxy)-6-nitroindan med Kokepunkt
KpQ Q3 187-190°C og med smp. 6l°c (hexan),
b) 6 - (4-klor-2-methy lf enoxy )-5-indany.lam in som olje,
c) N-j 6-(4-klor-2-met hy lf enoxy )-5-indanyl .-methansulfonamid
med smp. ll6°C.
Eksempel 7
Analogt med eksempel 1 fåes ved å gå ut fra 5-brom-6-nitroindan og 2-klorfenol: a) 5-(2-klorfenoxy)-6-nitroindan med kokepunkt Kp „ 175-178°C,
b) 6-(2-klorfenoxy)-5-indanylamin som olje,
c) ) N-[ 6-(2-klorfenoxy)-5-indanyl I-methansulfonamid med
smp. 120°C.
Eksempel 8
Analogt med eksempel 1 fåes ved å gå ut fra 5-brom-6-nitroindan og 3-klorfenol: a) 5-(, 3-klorfenoxy)-6-nitroindan med kokepunkt Kp O >v j„ 176-182 C,
D) 6-(3-klorfenoxy)-5-indanylamin som olje,
c) N- 6-(3-klorfenoxy)-5-indanyl ; -methansulfonamid med
smp. 109-111°C.
Eksempel 9
Analogt med eksempel L fåes ved å gå ut fra 5-brom-6-nitroindan og 2-f lu.irfenol : a) 5-(2-fluorfenoxy)-6-nitroindan med kokeounkt Kp 155-165^C og med smp. 47°C,
b) 6-(2-f Luorfenoscy )-5-inianyJ am in som :ilie,
c) N-i 6-(2-fluorfenoxy)-5-indanyl -methansulfonamid med
78°C
Eksempel 10
Analogt med eksempel 1 fåes ved å gå ut fra 5-brom-6-nitroindan og 2-klor-4-fluorfenol:
a) 5-(2-klor-4-fluorfenoxy)-6-nitroindan som olje,
b) 6-(2-klor~4-fluorfenoxy)-5-indanylamin med smp. 63°C,
c) N-j 6-(2-klor-4-fiuorfenoxy)-5-indanyl]-methansulfonamid
med smp. Q0°C.
Eksempel 11
Analogt med eksempel 1 fåes ved å gå ut fra 5-brom-6-nitroindan og 3,4-diklorfenol: a) 5-(3,4-diklorfenoxy)-6-nitroindan efter silicagelsøylerens-ning (system: tetraklormethan/eddiksyreethylester, 30/1)
som olje,
b) 6-(3,4-diklorfenoxy)-5-indanylamin med smp. 84°C,
c) N-f6-(3,4-diklorfenoxy)-5-indanyl]-methansulfonamid med
smp. 135°C
Eksempel 12
Analogt med eksempel 1 fåes ved å gå ut fra 5-brom-6-nitroindan og 4-bromfenol:
a) 5-(4-bromfenoxy)-6-nitroindan med kokepunkt Kp O ,03,
183-183 C,
b) 6-(4-bromfenoxy)-5-indanylamin med smp. 66°C,
c) N-[6-(4-bromfenoxy)-5-indanyl]-methansulfonamid med smp. 118°C
Eksempel 13
Analogt med eksempel 1 fåes ved å gå ut fra 5-brom-6-nitroindan og 2,4-diklorfenol: a) 5-(2,4-diklorfenoxy)-6-nitroindan, rensning gjennom en silicagelsøyle (system: tetraklormethan/eddiksyreethylester,
30/l) som olje,
b) 6-(2,4-diklorfenoxy)-5-indanylamin som olje,
c) N-[6-(2,4-diklorfenoxy)-5-indanyli-methansulfonamid med
smp. 90°C.
Eksempel 14
Analogt med eksempel 1 fåes ved å gå ut fra 5-brora-6-nitroindan og o-cresol: a) 5-nitro-6-(2-tolyloxy)-indan med kokepunkt KpQ Q^ l63-l66°C,
b) 6-(2-tolyloxy)-5-indanylamin som olje,
c) N-[6-(2-tolyloxy)-5-indanyl]-methansulfonamid med smp. 92°C.
Eksempel 15
Analogt med eksempel 1 fåes ved å gå ut fra 5-brom-6-nitroindan og 3-fluorfenol: a) 5-(3-fluorfenoxy)-6-nitroindan med kokepunkt KpQ 0^ 155-163°C,
b) 6-(3-fluorfenoxy)-5-indanylamin med smp. 49°C,
c) N-[6-(3-fluorfenoxy)-5-indanyl]-methansulfonamid med
smp. 102°C.
Eksempel 16
v
a) l4j6 g 5-brom-6-nitroindan, 1,2 g kobber (I) -klor, 12,4 fil thiofenol og 8,4 g kaliumcarbonat i 150 ml absolutt pyridin
kokes under tilbakeløp i 3 timer under nitrogen. Reaksjonsblandingen inndampes i vakuum og opparbeides som beskrevet i eksempel lia. Der omkrystalliseres fra eddiksyreethylester, og man får 8,1 g 5-fenylthio-6-nitroindan med smp. 112°C. b) En oppløsning av 9 g 5-fenylthio-6-nitroindan i l60 ml ethanol og 6,6 ml hydrazinhydrat tilsettes ved kokepunktet 5 g Raney-nikkel og kokes under tilbakeløp i 1,25 timer.
Katalysatoren frafiltreres, oppløsningen inndampes til krystallisasjon, og man får 7,1 g 6-fenylthio-5-indanylamin med smp. 80°C.
c) Det erholdte produkt omsettes som beskrevet i eksempel lic, hvorved man får N-(6-fenylthio-5-indanyl)-methansulfonamid
med smp. 115,5°C.
Eks em pel 17
Analogt med eksempel 16 får man ved å gå ut fra 5-brom-6-nitroindan og k- t-butylbenzenthiol :
a) 5-(4-t-butylfenylthio)-6-nitroindan med smp. 94°C,
b) 6-(4-t-butylfenylthio)-5-indanylamin med smp. 92°C,
c) n-[6-(4-t-butylfenylthio)-5-indanyl]-methansulfonamid med
smp. ll6°C.
E ksempel 18
Analogt med eksempel 16 får man ved å gå ut fra 5-brom-6-nitroindan og 4-fluor-benzenthiol:
a) 5-(4-fluorfenylthio)-6-nitroindan med smp. 106°C,
b) 6-(4~fluorfenylthio)-5-indanylamin med smp. 6o°C,
c) N- [ 6-(4-fluorfenylthio)-5-indanyl]-methansulfonamid med
smp. 139°C
Eksempe l 19
a) 2,4 g 5-brom-6-nitroindan, 2,25 g kalium-t-butylat og 2,9 g 4-klorbenzenthiol i 30 ml absolutt dimethylformamid under
nitrogen oppvarmes i 3 timer ved 6o°C. Der inndampes i vakuum, tilsettes eddiksyreethylester og utrystes tre ganger med 2 n natronlut. Der inndampes igjen, og- residuet renses på en silicagelsøyle (system: tetraklormethan: eddiksyreethylester, 25/1) og omkrystalliseres fra ethano. Man får 1,2 g 5-(4-klorfenylthio)-6-nitroindan med mp. 118°C.
b) Analogt med eksempel 16b fåes av dette: 6-(4-klorfenylthio)-5-indanylamin med smp. 63°C. c) Analogt med eksempel lc fåes av dette: N-i 6-(4-klorfenylthio)-5-indanylj-methansulfonamid med
smp. 109°C.
Eksempel 20
a) 4,8 g 5-brom-6-nitroindan, 4,5 g kalium-5-butylat, 4,4 g 2-pyridinthiol i 50 ml absolutt dimethylformamid oppvarmes
ved 80 C i 3 timer under nitrogen. Der inndampes i vakuum, residuet tilsettes eddiksyreethylester og utrystes fire ganger med vann. Eddiksyreethylesterfasen inndampes, og
residuet renses på en silicagetsøyle (system: cyclohexan/ eddiksyreethylester, 4/1). Efter krystallisasjon fra ethanol fåes 3,3 g 5-nitro-6-(2-pyridylthio)-indan med smp. 74°C. b) Analogt med eksempel l6b fåes av dette: 6-(2-pyridylthio)-5-indanylamin med smp. 126°C. c) Analogt med eksempel lc fåes av dette:
N-T 6-(2-pyr idylthio)-5-indanyl]-methansulfonamid med
smp. l4l°C.
Eksempel 21
a) 7,2 g 5-brom-6-nitroindan og 3,9 g 4-pyrid:inthiol i 120 ml dimethylsulfoxyd oppvarmes med 3,6 g nat riumhydrogencarbonat
i 7 timer ved 50 C under nitrogen. Reaksjonsblandingen inndampes, residuet oppløses i kloroform/vann og utrystes tre ganger med vann. Der inndampes og renses på en silica-gelsøyle (system: cyclohexan/eddiksyreethylester, l/l).
Efter krystallisasjon fra ethanol fåes 2 g 5-(4-pyridylthio)-6-nit roindan med smp. H3°c. b) Analogt med eksempel 16b fåes av dette: 6-(4-pyridylthio)-5-indanylamin med smp. l40°C. c) Analogt med eksempel lc fåes av dette:
N-[ 6-(4-pyridylthio)-5-indanyl]-methansulfonamid med
156°C.
Eksempel 22
Analogt med eksempel 1 fåes ved å gå ut fra 5-brom-6-nitroindan og 3~klorpyridin:
a) 6 - (3-pyridyloxv)-5 -nitroindan som olje,
b) 6-( 3-pyr Ldvlo>cy )-5-i-ndanyl amin med smp. 118°C,
c) N-, 6-( 3-pyridylox-y )-5-indanyl :-methyl sulf onamid med smp. 12o°C.
Ek sempel 2 3
1,1 9 6-fenoxy-5-indanylamin oppløses i 15 ml absolutt pyridin og tilsettes ved 0''c i løpet av 10 minutter 1,6 ml trifluor-methansulfonsyreanhydrid i 3 il absolutt benzen. Man omrører i 3 timer ved 0°C og i 16 timer ved værelseternperauur, inndamper i vakuum, tar residuet opp i kloroform og utryster tre ganger med 1 n saltsyre. Derpå inndam<p>es kloroformfasen i vakuum, residuet renses på en silicagelsøyle (system: kloroform) og omkrystalliseres fra hexan. Man får O,74 g N-(6-fenoxy-5-indanyl)-trifluor-methansulfonamid med smp. QO°C.
Eksempel 24
Analogt med eksempel 23 fåes fra 6-fenylthio-5-indanylamin: N-(6-fenylthio-5-indanyl)-trifluormethansulfonamid, smp. 67°C.
Eksempel 25
Analogt med eksempel 23 får man fra 6-(4-fluorfenoxy)-5-indanylamin: N-| 6-(4-fluorfenoxy)-5-indanyl]-t rifluormethansulfonamid, smp.l23°C.
Eksempel 26
Analogt med eksempel 23 fåes fra 4-klorfenoxy-5-indanylamin: N-j 6-(4-klorfenoxy)-5-indanyl]-trifluormethansulfonamid, smp. 139°C.
Eksempel 27
Analogt med eksempel 23 fåes fra 6-fenoxy-5-indanylamin med klormethansulfonsyreanhydrid: N-(6-fenoxy-5-indanyl)-klormethansulfonamid med smp. 73°C.
Eksempel 2 8
Analogt med eksempel 23 fåes fra 6-fenoxy-5-indanylamin med ethansulfonsyreanhydrid:
N-(6-fenoxy-5-indanyl)-ethansulfonamid med smp. 89°C.
Eksempe l 29
a) 11 g 5-nitro-6-fenoxyindan og 17,3 9 bis-dimethylamino-t-butoxymethan oppvarmes i løpet av 60 minutter til 155°C og
holdes ved denne temperatur i 60 minutter, hvorved t-butanol avdestilleres. Derpå inndampes i vakuum, tilsettes 50 ml ethanol og avsuges. Man får 9,2 g 1-dimethylaminomethylen-5-nitro-6-fenoxyindan med smp. 97°C.
b) 6,2 g av dette enamin oppløses i 1O0 ml kloroform og ozoniseres ved -35°C. Efter filtrering over 30 g silicagel
med kloroform, inndampning og krystallisasjon fra 30 ml ethanol, fåes 3,8 g 5-nitro-6-fenoxy-1-indanon med smp. 105°C.
c) 1,58 g av derte nitroketon oppløses i 20 ml ethanol og-
10 ml dioxan. Oppløsningen tilsettes 0,74 g hydrazinhydrat, og ca. 1,5 g Raney-nikkel (oppslemmet i ethanol) innføres porsjonsvis ved 35°C. Efter 60 minutters tilbakeløpskok-ning avkjøles, filtreres og inndampes. Omkrystallisasjon fra ethanol gir 1,22 g 5-amino-6-fenoxy-1-indanon med smp. 17o°C. d) 1,2 g av dette aminoketon i 12 ml pyridin inndampes i vakuum ved 0°C, residuet tilsettes isvann og avsuges. Bunnfallet
oppløses i fortynnet natronlut, og den filtrerte oppløsning surgjøres med saltsyre. Avsugning og omkrystallisasjon fra ethanol gir 1,35 g 5-methylsulfonylamino-6-fenoxy-l-indanon med smp. 175°C.
Eksempel 30
Analogt med eksempel 29 fåes ved å gå ut fra 6-(4-klor-fenoxy)-5-nit roindan: a) 6-(4-klorfeno^y)-l-dlmethylaminomethylen-5-nitroindan med smp. 117°C,
b) 6-(4-klorfenoxy)-5-nitro-1-indanon med smp. 131°C,
c) 5-amino-6-(4-klorfenoxy)-1-indanon med smp. l69°C,
d) 6-(4-klorfenoxy)-5-methylsulfonylamino-l-indanon med
smp. 185°C.
Eksempel 31
Analogt med eksempel 29 fåes ved å gå ut fra 6-(4-fluor-fenoxy)-5-nit roindan: a) 1-dimethylaminomethylen-6-(4-fluorfenoxy)-5-nitroindan med smp. 128°C,
b) 6-(4-f luorfen<ixy )-5-nit ro-1-indanon med smp. 150°C,
c) 5-amino-6-(4-fluorfenoxy)-1-indanon med smp. l67°c,
d) 6-(4-fluorfenoxy)-5-methy1sulfonylamLno-1-indanon med
smp. l44°C.
Eksempel 32
Analogt med eksempel 29 fåes ved å gå ut fra 6»(3-klor-fenoxy)-5-nitroindan:
a ) 6- (3 -j;:lorf enoxy ) -l-dimethylaminomethylen-5-nit roindan med
Q
smp. 78 C,
b) 6-(3-klorfenoxy)-5-nitro-l-indanon raed smp. 92°C,
c) 5-amino-6-(3-klorfenoxy)-1-indanon med smp. l62°C,
6-(3-klorfenoxy)-5-methylsulfonylamino-1-indanon med
smp. 129°C.
E ksempel 33
Analogt med eksempel 29 fåes ved å gå ut fra 6-(2-fluor-fenoxy)-5-n it roindan: a) 1-dimethylaminomethylen-6-(2-fluorfenoxy)-5-nitroindan med smp. 122°c,
b) 6-(2-f luorf enoxy) -5-nitro-l-indanon med smp. lo4°C,
c) 5-amino-6-(2-fluorfenoxy)-1-indanon med smp. l64°C,
d) 6-(2-fLuorfenoxy)-5-methylsulfonylamino-l-indanon med
smp. 119°c.
Eksempel 34
3,17 g 5-methylsulfonylamino-6-fenoxy-l-indanon blir i pyridin ved -40°C tilsatt 27 ml av en 10%-ig oppløsning av lithiumdiisopropylamid i hexan. Efter 2o minutter ved -35°C tildryppes 4,4 g difenyldisulfid i IO ml pyridin. Efter 1 time ved -10°C og 2 timer ved 20°C tildryppes 10 ml 2-propanol. Efter inndarapning i vakuum taes opp i vann, filtreres, surgjøres og ekstraheres med kloroform. Inndampning og kromatografi av residuet over 240 g silicagel med kloroform som elueringsmiddel gir først 400 mg 5-methylsulfonylamino-6-fenoxy-2,2-bis-(fenylthio)-1-indanon med smp. l62°C, og deretter 2 g 5-methylsulfonylamino-6-fenoxy-2-fenylthio-l-indanon med smp. 86°C.
E ksempel 3 5
1,7 g 5-methylsulfonylamino-6-fenoxy-2-fenylthio-1-indanon oppløses i 20 ml methanol og tilsettes ved 20°C 4 ml av en 1 n opp-løsning av perselensyre (Lit.: J. Drabowicz, M. Mikolajczyk,
Synthesis 1978, 758) i methanol. Efter 30 minutter tilsettes 30 ml vann, methanol fjernes i vakuum og kryst allisatet avsuges. Man får 1,7 g 5-methylsulfonylamino-6-fenoxy-2-fenylsulfinyl-l-indanon med smp. 120°C.
Eksempe l 36
600 mg 5-methylsulfonylamino-6-fenoxy-2-fenylthio-l-indanon
i 5 ml eddiksyre med 2 ml 30%-ig hydrogenperoxyd holdes ved QO°C
i 30 minutter» Derpå avkjøles til 20<J>C, 15 ml isvann tilsettes, og krystallisatet avsuges. Omkrystallisasjon fra ethanol gir 400 mg 5-methylsulfonylamino-6-fenoxy-2-fenylsulfony1-1-indanon med smp. 180°C.
Eksempel 37
4,12 g 5-methylsulfonylamino-6-fenoxy-1-indanon oppløses i 45 ml methanol og 13 ml 1 n natronlut. Ved 5°C tilsettes 0,98 g natriumborhydrid. Efter l6 timer ved 20°C inndampes, tilsettes isvann, nøytraliseres med saltsyre og ekstraheres med kloroform. Vasking av kloroformoppløsningen med vann, inndampning og om-kryst allisas jon av residuet fra toluen gir 3,3 9 5-methylsulfonyl-amino-6-fenoxy-1-indanol med smp. 96°C.
Eksempel 38
1,97 g 5-methylsulfonylamino-6-fenoxy-l-indanon i 40 ml methanol og 13 ml vann kokes med 1,1 g natriumacetattrihydrat og 1,05 g hydroxylamin-hydroklorid i 6 timer. Avkjøling og avsuging gir 1,8 9 N-(1-hydroxyimino-6-fenoxy-5-indanyl)-methansulfonamid med smp. 2l6°C.
Eksempel 39
3,17 g 5-methylsulfonylamino-6-fenoxy-l-indanon behandles som i eksempel 48 beskrevet med methoxyamin-hydroklorid. Man får 2,8 g N-(1-methoxyimino-6-fenoxy-5-indanyl)-methansulfonamid med 178°C.
Eksempel 40
3,17 g 5-methylsulfonylamino-6-fenoxy-l-indanon omrøres i
80 ml methylglycol ved SO°C med 2 g p-toluensulfonsyre-hydrazid med noen få dråper saltsyre i 30 minutter. Avkjøling og avsugning gir 3,74 9 N- 1 -(4-toluensulfonylhydrazono)-6-fenoxy-5-indany1 i - methansulfonamid med smp. 252°c.
Eksempel 4l
3,33 g N-(l-hyd roxyim ino-6-fenoxv-5-indany1)-met hansulfon-amid hydrogeneres i loo ml methanol i nærvær av ammoniakk og 0,5 g nikkel ved 90°C og 75 atm. Efter filtrering og inndampning
renses residuet over en silicagelsøyle (systera: kloroform/methanol, 1/1). Opptagelse i natronlut og surgjøring til pH 6 med eddiksyre gir 715 mg 5-methylsulfonylamino-6-fenoxy-l-indanylamin som acetat med smp. 175°C.
Eksempel 42
a) 35 g l-dimethylaminomethylen-5-nitro-6-fenoxyindan omrøres i 75 timer ved 20°C med 31 g hydroxylamin-O-su.lfonsyre i en
blanding av 250 ml ether, 50 ml dioxan og 250 ml vann.
Efter tilsetning av lOO ml vann fraskilles den organiske fase, vaskes med vann, tørres og inndampes. Residuet om-kryst alliseres fra 2-propanol og gir 20 g 5-nitro-6-fenoxy-indan-l-carbonitril med smp. 78°C. b) 10 g av denne nitroforbindelse hydrogeneres i 95 ml ethanol og 25 ml dioxan i nærvær av 0,9 g palladium på kull (10%).
Filtrering, inndampning og omkrystallisasjon av residuet
fra diisopropylether gir 8 g 5-amino-6-fenoxyindan-l-carbo-nxtril med smp. 108 C.
c) 1,72 g av denne aminoforbindelse i IO ml pyridin omsettes ved -2°C med 1,04 g methansulfonsyreklorid. Efter 3 timer
ved 20°C inndampes, taes opp i kloroform, oppløsningen vaskes med 1 n saltsyre og vann, tørres og inndampes. Om-krystallisas jon av residuet fra 2-propano.l gir 1,54 g 5-methylsulfonylamino-6-fenoxyindan-l-carbonitril med smp. 110°C.
Eksempel 43
3,58 g 5-methylsulfonylamino-6-fenoxy-2-fenylthio-l-indanon oppløses i 35 ml methanol og 9 ml 1 n natronlut. Ved 5°C tilsettes 680 mg nat riumborhydrid porsjonsvis. Efter 16 timer ved 2o°C innstilles på pH 8,2 med 22 ml 1 n saltsyre, og det utfalte krystallisat (3,50 g) avsuges. Kromatografi over 120 g silicagel med kloroform gir så 2,5 g cis-5-methylsulfonylamino-6-fenoxy-2-fenylthio-1-indanol med smp. 135°C.
El<s_einpeT_ 44.
a) 47j 3 g 5-fluor-1 -indanon behandles i 3 timer ved 0° til -5°C med 220 ml rykende salpetersyre. Reaksjons blandingen
helles i isvann, ekstraheres med kloroform, og kloroformfasen vaskes nøytral og inndampes. Omkrystallisasjon av residuet fra ethanol gir 20,4 9 5-fiuor -6-nitro-l-indanon med smp. 89°C. b) 20,3 g av denne forbindelse i 130 ml dimethylsulfoxyd behandles i 3 timer vad 50°C med 9,8 g f enol og natriuin-hydrogencarbonat. Inndampning i vakuum, opptagelse av residuet i kloroform, vasking med saltsyre og natronlut, tørr-ing og inndampning og omkrystallisasjon av residuet fra ethanol gir 8}2 g 6-nitro-5-fenoxy-L-indanon med smp. 103°C. c) 10,2 g av denne forbindelse reduseres som beskrevet i eksempel 39c. Man får 5,7 g 6-amino-5-fenoxy-l-indanon med
smp. 133°C
d) 4»57 g av denne forbindelse omsettes med methansulfonylklorid som beskrevet i eksempel 39d. Man får 5,9 g 6-methylsulfonylamino-5-fenoxy-l-indanon med smp. 156°C.
Eksempel 4 5
Analogt med eksempel 38 fåes av 6-methy1sulfonylamino-5-fenoxy-l-indanon-N- (1 -hydroxy imino-5-f enoxy-6-indany 1) -met han-sulfonamid med smp. 200°C.
Eksempel 46
Analogt med eksempel 37 får man fra 6-methylsulfonylamino-5-fenoxy-l-indanon:
6-methylsulfonylam ino-5-f enoxy-1-indano.l med smp. J56°C.
<\>
i
Eksempel L\ J
a) 1,56 g 5-fluor-6-nitro-l-indanon behandles i 28 ml dimethyl-sulf oxyd i 30 minutter ved 20°C med 0,8 g natriumhydrogen-carbonat og 0,88 9 thiofenol. Inndampning i vakuum, opptagelse av residuet i kloroform, vasking med saltsyre og natronlut, tørring, inndampning og omkrystallisasjon av residuet fra ethanol gir 1,27 9 6-nitro-5-fenylthio-1-indanon med smp. l46°c. b) 0,52 g av denne forbindelse reduseres som i eksempel 29c beskrevet. Man får 153 m9 6-amino-5-fenylthio-l-indanon
med smp. 142°C.
c) 250 mg av denne forbindelse omsettes som i eksempel 29d beskrevet med methansulfonylklorid. Man får 270 mg 6-methylsulfonylamino-5-fenylthio-l-indanon med smp. l66°C.
Eksempel 48
0,91 g N-(6-fenoxy-5-indanyl)-methansulfonamid oppløses i
3 ral eddiksyre og 0,72 ml eddiksyreanhydrid, og ved 5-10°C tilsettes en oppløsning av 0,39 9 krom(VI)-oxyd i 0,3 ml vann og 2 ml eddiksyre. Efter 60 timer ved 20°C helles reaksjonsblandingen i vann, og forbindelsen ekstraheres med eddiksyreester. Nøytralvaskning og inndampning av oppløsningen gir en blanding
av forbindelser. Ved kromatografi over silicagel fåes 0,47 g 5-methylsulfonylamino-6-fenoxy-l-indanon med smp. 175°C
Claims (1)
- Analogifremgangsmåte ved fremstilling av terapeutisk aktive indanyIderivater med den generelle formel:hvor Ar er fenyl eller pyridyl som eventuelt er suostituert med halogen, alkyl med 1-4 carbonatomer eller trifluormethyl,X er oxygen eller svovel,R1 er alkyl med 1-4 carbonatomer som eventuelt er substituert med fluor eller klor, ogA er en gruppe:hvorY er oxo, hydroxyimino, alkoxyimino med 1-4 carbonatomer, fenylhydrazono eller p-toluensulfonylhydrazono,Z er hydroxy, amino eller cyano,n er 0, 1 eller 2, ogR2 er fenyl,og fysiologisk godtagbare salter med baser eller syrer, karakterisert ved at en forbindelse med den generelle formel:hvor Ar, X og A er som ovenfor angitt, kondenseres med et sul fon - syrederivat med den generelle formel:hvor R er som ovenfor angitt, og W er halogen eller gruppen R SOpO-, og eventuelt a) ved fremstilling av indanderivater med den generelle formel I hvor A er -COCH2CH2-, oxyderes et indanderivat med den generelle formel I hvor A er -CH2CH2CH2~ eller b) ved fremstilling av indanderivater med den generelleomsettes et indanderivat med den generelle formel I hvor A er -COCH2CH2- i nærvær av en sterk base med et disulfid med den generelle formel:hvor R2 er som ovenfor angitt,og eventuelt oxyderes den erholdte thioforbindelse med den generelle formel I til det tilsvarende sulfoxyd eller sulfon, eller c) ved fremstilling av indanderivater med den generelle formel I hvor Y er hydroxyimino, alkoxyimino med 1-4 carbonatomer, fenylhydrazono eller en p-toluensulfonylhydrazono, kondenseres et indanderivat med den generelle formel I hvor Y er oxo med det tilsvarende oxim eller hydrazon, ellerd) ved fremstilling av et indanderivat med den generelle formel I hvor Z er hydroxy eller amino, reduseres et indanderivat med den generelle fornel I hvor A erog at en således erholdt forbindelse eventuelt overføres til et salt derav.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19782833202 DE2833202A1 (de) | 1978-07-27 | 1978-07-27 | Neue indanyl- und tetralinylamide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
DE19792923937 DE2923937A1 (de) | 1979-06-11 | 1979-06-11 | Neue indanyl-derivate, ihre herstellung und verwendung |
Publications (3)
Publication Number | Publication Date |
---|---|
NO792474L NO792474L (no) | 1980-01-29 |
NO147560B true NO147560B (no) | 1983-01-24 |
NO147560C NO147560C (no) | 1983-05-04 |
Family
ID=25775214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO792474A NO147560C (no) | 1978-07-27 | 1979-07-26 | Analogifremgangsmaate ved fremstilling av terapeutisk aktive indanyl-derivater |
Country Status (23)
Country | Link |
---|---|
US (1) | US4244960A (no) |
EP (1) | EP0009554B1 (no) |
AU (1) | AU532405B2 (no) |
BG (1) | BG36197A3 (no) |
CA (1) | CA1124724A (no) |
DD (1) | DD145101A5 (no) |
DE (1) | DE2965279D1 (no) |
DK (1) | DK159269C (no) |
DZ (1) | DZ206A1 (no) |
EG (1) | EG14394A (no) |
ES (1) | ES482918A1 (no) |
FI (1) | FI71306C (no) |
FR (1) | FR2433512A1 (no) |
GB (1) | GB2025973A (no) |
GR (1) | GR73006B (no) |
IE (1) | IE48783B1 (no) |
IL (1) | IL57901A (no) |
NO (1) | NO147560C (no) |
NZ (1) | NZ191100A (no) |
PH (1) | PH20604A (no) |
PL (1) | PL126816B1 (no) |
PT (1) | PT69986A (no) |
RO (1) | RO78632A (no) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3103372A1 (de) * | 1981-01-27 | 1982-09-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue indanyl-derivate, ihre herstellung und verwendung |
DE3208079A1 (de) * | 1982-03-04 | 1983-09-08 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue indanyl-derivate, ihre herstellung und verwendung |
US4555406A (en) * | 1983-09-06 | 1985-11-26 | Schering Aktiengesellschaft | Indanyl derivatives, their preparation and use |
DE3343331A1 (de) * | 1983-11-28 | 1985-06-05 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur herstellung von indanyl-derivaten und deren verwendung |
WO1988006155A1 (en) * | 1987-02-10 | 1988-08-25 | Idemitsu Kosan Company Limited | Trifluoromethanesulfonamide derivatives, process for their preparation, and herbicides containing same |
US5035739A (en) * | 1987-02-10 | 1991-07-30 | Idemitsu Kosan Company Limited | Trifluoromethanesulfonamide derivative and a herbicide containing the same |
JPH0753725B2 (ja) * | 1987-10-08 | 1995-06-07 | 富山化学工業株式会社 | 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤 |
GB9003551D0 (en) * | 1990-02-16 | 1990-04-11 | Ici Plc | Heterocyclic compounds |
US5604260A (en) * | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5409944A (en) * | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
WO1996023786A1 (en) * | 1995-01-31 | 1996-08-08 | Merck Frosst Canada Inc. | 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2 |
ES2138902B1 (es) * | 1997-05-19 | 2000-09-16 | Salvat Lab Sa | "5-ariltio-6-sulfonamido-3(2h)-benzofuranonas como inhibidores de la cox-2". |
DE10142660A1 (de) | 2001-08-31 | 2003-03-20 | Aventis Pharma Gmbh | Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
DE10142668A1 (de) | 2001-08-31 | 2003-03-20 | Aventis Pharma Gmbh | Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
DE10142667B4 (de) | 2001-08-31 | 2004-06-09 | Aventis Pharma Deutschland Gmbh | C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel |
DE10142661B4 (de) * | 2001-08-31 | 2004-06-09 | Aventis Pharma Deutschland Gmbh | Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel |
DE10142659A1 (de) * | 2001-08-31 | 2003-03-20 | Aventis Pharma Gmbh | Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
DE10142662B4 (de) | 2001-08-31 | 2004-07-08 | Aventis Pharma Deutschland Gmbh | Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel |
DE10142666A1 (de) * | 2001-08-31 | 2003-03-20 | Aventis Pharma Gmbh | Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
DE10142722A1 (de) * | 2001-08-31 | 2003-03-27 | Aventis Pharma Deutschland GmbH, 65929 Frankfurt | C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2921958A (en) * | 1954-09-03 | 1960-01-19 | Ruhrchemie Ag | 4.5.6.7.10.10-hexachloro-4.7-methylene-4.7.8.9-tetrahydroindane-sulfonic acid, saltsand acid amides thereof |
US3288852A (en) * | 1964-05-08 | 1966-11-29 | Dow Chemical Co | Anthracene dialkanesulfonamides |
AR206496A1 (es) * | 1972-07-03 | 1976-07-30 | Riker Laboratories Inc | Procedimiento para la preparacion de 2-fenoxi-4-nitro-alquil o haloalquilsulfonanilidas |
US4087549A (en) * | 1972-12-06 | 1978-05-02 | Merck & Co., Inc. | Sulphonic acid containing indenyl derivatives |
US4086255A (en) * | 1974-04-15 | 1978-04-25 | Minnesota Mining And Manufacturing Company | Perfluoroalkylsulfonamidoaryl compounds |
GB1472843A (en) * | 1976-02-12 | 1977-05-11 | Pfizer Ltd | Benzene sulphonamides |
GB2009146B (en) * | 1977-11-29 | 1982-03-24 | Ishihara Sangyo Kaisha | Sulphonanilide copmouds and herbicidal compositions therof |
-
1979
- 1979-07-20 DE DE7979102566T patent/DE2965279D1/de not_active Expired
- 1979-07-20 EP EP79102566A patent/EP0009554B1/de not_active Expired
- 1979-07-24 BG BG044445A patent/BG36197A3/xx unknown
- 1979-07-24 NZ NZ191100A patent/NZ191100A/xx unknown
- 1979-07-24 DD DD79214579A patent/DD145101A5/de unknown
- 1979-07-25 GR GR59694A patent/GR73006B/el unknown
- 1979-07-25 EG EG448/79A patent/EG14394A/xx active
- 1979-07-25 DZ DZ795518A patent/DZ206A1/fr active
- 1979-07-25 PL PL1979217384A patent/PL126816B1/pl unknown
- 1979-07-26 DK DK315979A patent/DK159269C/da not_active IP Right Cessation
- 1979-07-26 PT PT69986A patent/PT69986A/pt unknown
- 1979-07-26 GB GB7926016A patent/GB2025973A/en not_active Withdrawn
- 1979-07-26 FI FI792347A patent/FI71306C/fi not_active IP Right Cessation
- 1979-07-26 PH PH22819A patent/PH20604A/en unknown
- 1979-07-26 FR FR7919301A patent/FR2433512A1/fr active Pending
- 1979-07-26 IL IL57901A patent/IL57901A/xx unknown
- 1979-07-26 NO NO792474A patent/NO147560C/no unknown
- 1979-07-27 US US06/061,779 patent/US4244960A/en not_active Expired - Lifetime
- 1979-07-27 ES ES482918A patent/ES482918A1/es not_active Expired
- 1979-07-27 AU AU49325/79A patent/AU532405B2/en not_active Ceased
- 1979-07-27 RO RO7998285A patent/RO78632A/ro unknown
- 1979-07-27 CA CA332,665A patent/CA1124724A/en not_active Expired
- 1979-08-08 IE IE1422/79A patent/IE48783B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PT69986A (de) | 1979-08-01 |
IL57901A0 (en) | 1979-11-30 |
CA1124724A (en) | 1982-06-01 |
NO792474L (no) | 1980-01-29 |
RO78632A (ro) | 1982-04-12 |
PL126816B1 (en) | 1983-09-30 |
GB2025973A (en) | 1980-01-30 |
PH20604A (en) | 1987-02-24 |
EP0009554B1 (de) | 1983-04-27 |
IE791422L (en) | 1980-01-27 |
FI71306C (fi) | 1986-12-19 |
IL57901A (en) | 1983-11-30 |
FI792347A (fi) | 1980-01-28 |
DK159269C (da) | 1991-02-18 |
FI71306B (fi) | 1986-09-09 |
DZ206A1 (fr) | 2004-09-13 |
DD145101A5 (de) | 1980-11-19 |
BG36197A3 (en) | 1984-09-14 |
NO147560C (no) | 1983-05-04 |
US4244960A (en) | 1981-01-13 |
NZ191100A (en) | 1982-03-30 |
PL217384A1 (no) | 1981-11-13 |
FR2433512A1 (fr) | 1980-03-14 |
GR73006B (no) | 1984-01-24 |
AU532405B2 (en) | 1983-09-29 |
ES482918A1 (es) | 1980-05-16 |
DE2965279D1 (en) | 1983-06-01 |
EG14394A (en) | 1983-12-31 |
DK159269B (da) | 1990-09-24 |
AU4932579A (en) | 1980-02-07 |
DK315979A (da) | 1980-01-28 |
IE48783B1 (en) | 1985-05-15 |
EP0009554A1 (de) | 1980-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO147560B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive indanyl-derivater | |
AU642502B2 (en) | Derivatives of hydroxy and alkoxy pyridines | |
FI69451B (fi) | Foerfarande foer framstaellning av antiinflammatoriska 4,5-diaryl-2-nitroimidazoler | |
US4198421A (en) | Antiinflammatory 2-substituted-dibenzo[2,3:6,7]oxepino[4,5-d]imidazoles | |
US3642785A (en) | Indenyl-3-aliphatic amines | |
IL42640A (en) | Substituted 2'-phenoxyalkane-sulfonanilides | |
NO319612B1 (no) | Benzopyranderivater som har leukotrien-antagonistisk virkning, fremgangsmate for fremstilling og anvendelse derav | |
JPH06135934A (ja) | ピリジン誘導体又はその塩を含有するホスホリパーゼ▲a2▼阻害剤、抗炎症剤又は抗膵炎剤 | |
TWI468110B (zh) | Preparation of 6-Aryloxyquinoline Derivatives and Intermediates thereof | |
US3933835A (en) | New aliphatically substituted aryl-chalcogeno-hydrocarbon derivatives | |
JPH04364168A (ja) | スルホンアミドピリジン化合物 | |
JPS6310696B2 (no) | ||
NO174465B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk 1-acyl- 2,3-dihydro-4-(1H)-kinolinon-4-oksimderi-vater | |
CS216205B2 (en) | Method of making the derivatives of the 1,4-diphenylpyrazole | |
EP1592666A1 (en) | 2,3 -bipyridines derivatives as selective cox-2 inhibitors | |
CA1297109C (en) | 2-pyridinyl or 2-quinolinyl-methoxy-thiophene derivatives | |
CA2147495A1 (en) | N-t-butylaniline analog and lipid level depressant containing the same | |
US4000183A (en) | Adamantyl-phenoxy- and phenylthio-alkyl-alkanoyl esters | |
EP1432684A2 (en) | Pyridinic sulfonamide derivatives, method of production and use thereof | |
AU2002337116A1 (en) | Pyridinic sulfonamide derivatives, method of production and use thereof | |
CA1122601A (en) | 4-(2'-pyridylamino)phenylacetic acid derivatives | |
JPS6353984B2 (no) | ||
PL145950B1 (en) | Method of obtaining 1,3-diacyl-2-ketoindoles | |
US4013719A (en) | Adamantyl phenoxy alkylamides | |
SK12832002A3 (sk) | Deriváty 2-fenylpyrán-4-ónu |